Clinical trial
Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
NCT00447694 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00447694 |
|---|---|
| Title | Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment |
| Official title | An Open Label Trial Evaluating Cardiac T2* in Beta-thalassemia Patients on Deferasirox (ICL670) Treatment for 18 Months |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Beta-thalassemia, Iron Overload |
| Intervention type | Drug |
| Interventions | Deferasirox |
| Enrollment | 30 |
| Start date | Feb 1, 2006 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Mar 15, 2007 |
| Last update posted | Jun 14, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: